GlassScriptPhysician profile
Ali Nayfeh
NPI 1932655651
$12,473.29
in general payments reported to CMS, 2019-2025
25 companies · $10K in 2025
The $10K reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $169 · 2022: $168 · 2023: $714 · 2024: $1,283 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $7,000 · Food and Beverage: $4,112 · Travel and Lodging: $1,024.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $7,000.00 |
| Food and Beverage | $4,111.70 |
| Travel and Lodging | $1,024.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $8,054.36 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $1,001.05 | 2021-2025 | Fasenra, Airsupra, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $594.94 | 2022-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Grifols USA, LLC | $489.24 | 2022-2025 | Prolastin-C Liquid |
| Glaxosmithkline, LLC. | $319.30 | 2023-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astellas Pharma US INC | $233.70 | 2021-2022 | |
| Amgen INC. | $220.98 | 2023-2025 | Tezspire, Tavneos |
| Insmed, INC. | $215.62 | 2023-2025 | Arikayce, Brinsupri |
| Genzyme Corporation | $196.69 | 2023-2025 | |
| Harmony Biosciences LLC | $172.74 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $170.22 | 2023-2025 | Xywav |
| Viatris Specialty LLC | $137.51 | 2025 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $133.64 | 2025 | Dupixent |
| Abbvie INC. | $114.43 | 2023-2025 | |
| Electromed, INC. | $72.46 | 2024-2025 | Smartvest |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Resmed Corp | $72.16 | 2024-2025 | |
| Verona Pharma, INC. | $62.93 | 2025 | Ohtuvayre |
| Axsome Therapeutics, INC. | $46.85 | 2024-2025 | Sunosi |
| Abiomed | $46.50 | 2025 | |
| Philips North America LLC | $25.84 | 2023 | |
| Mallinckrodt Hospital Products INC. | $21.74 | 2023 | Acthar |
| Lilly USA, LLC | $21.45 | 2025 | Zepbound |
| Gilead Sciences, INC. | $21.33 | 2024 | Veklury |
| Actelion Pharmaceuticals US, INC. | $14.23 | 2024 | Uptravi, Opsumit |
| Mylan Specialty L.P. | $13.38 | 2024 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Nayfeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.